Progress in research on tumor immune PD?1／PD?L1 signaling pathway in malignant bone tumors

VernacularTitle:恶性骨肿瘤中程序性死亡蛋白1及其配体的临床研究进展
Author: Haifeng HUANG ¹ ; Hua ZHU ; Xianteng YANG ; Xiaoyi GUO ; Shanshan LI ; Quan XIE ; Xiaobin TIAN ; Zhi YANG
Author Information

1. 贵州省人民医院骨科
Keywords: Programmed cell death protein 1,PD?1; Programmed cell death?Ligand 1,PD?L1; Bone neoplasms
From: Chinese Journal of Oncology 2019;41(6):410-414
CountryChina
Language:Chinese
Abstract: Programmed death receptor 1 (PD?1) and its ligand PD?L1 have been shown to play an important role in evading the immune system. In recent years, PD?1／PD?L1 blockade has shown significant clinical effects in many malignancies, including malignant melanoma, renal cell carcinoma, classic Hodgkin lymphoma, non?small cell lung cancer and so on. PD?1／PD?L1 signaling pathway has become a new target of immunotherapy in patients with malignant tumors. However, there are few researches on immunotherapy in malignant bone tumors, and the progress of clinical research on PD?1／PD?L1 remains to be elucidated. This review started from the mechanism of PD?1／PD?L1 signaling in tumor immunity, and analyzed the application prospect of PD?1／PD?L1 antibodies in malignant bone tumors. We hope to provide a theoretical basis for the treatment of malignant bone tumors based on PD?1／PD?L1 signaling pathway in China.